EchoNous
| Type | Private |
|---|---|
| Industry | Medical technology Medical devices |
| Founded | 2016 in Redmond, Washington, United States |
| Founders | Kevin Goodwin Niko Pagoulatos |
| Headquarters | Redmond, Washington , United States |
| Products | Point-of-care ultrasound devices |
| Services | AI-assisted ultrasound software POCUS imaging systems |
| Website | echonous |
EchoNous is an American medical technology company that develops point-of-care ultrasound (POCUS) devices and AI-assisted imaging software for bedside clinical use. The company is based in Redmond, Washington.[1][2]
History
EchoNous was founded in 2016 in Redmond by Kevin Goodwin and Niko Pagoulatos.[3]
In 2017, EchoNous received a $35 million investment from KKR to expand its Uscan bladder scanner business and develop a new AI-driven ultrasound platform.[4][5][6]
In March 2020, the U.S. Food and Drug Administration (FDA) cleared Kosmos through the 510(k) process.[7] In 2021, EchoNous raised $60 million from Kennedy Lewis Investment Management to support the commercial launch of Kosmos.[8] Later that year, the FDA cleared the company's Lexsa linear probe for use with the Kosmos platform.[9]
In 2022, EchoNous raised $57 million in a Series D round.[10][11] That year, the company also partnered with Samsung so that Kosmos could run on Galaxy Tab Active Pro tablets instead of only on EchoNous's display.[11][12]
In 2023, EchoNous raised an additional $7 million.[13] The FDA issued additional 510(k) clearances for Kosmos in 2024 and 2025.[14][15]
Kosmos
Kosmos is a hand-carried ultrasound system that combines ultrasound imaging with AI-based guidance, image labeling, and automated cardiac measurements.[16][17][13] FDA-cleared indications for the platform include cardiac, thoracic/lung, abdominal, peripheral vascular, and image-guidance applications.[7] The platform was later expanded with the Lexsa linear probe, and it is compatible with select Apple iOS and Android tablets.[9]
References
- ↑ "Redmond-based EchoNous taps new CEO". Puget Sound Business Journal. May 17, 2023.
- ↑ https://www.bizjournals.com/seattle/news/2017/09/29/echonous-miniaturized-ultrasound-uscan-investment.html
- ↑ "EchoNous Inc - Company Profile and News". Bloomberg.
- ↑ Schlosser, Kurt (September 28, 2017). "EchoNous announces $35M in new funding for mini, AI-driven ultrasound devices". GeekWire.
- ↑ "Redmond ultrasound-device maker EchoNous raises $35M from KKR". The Seattle Times. September 28, 2017.
- ↑ https://www.reuters.com/article/business/echonous-parent-company-of-signostics-announced-a-new-35-million-dollar-inves-idUSFWN1M90AQ/
- 1 2 "510(k) Premarket Notification: K193518". U.S. Food and Drug Administration.
- ↑ "Redmond's EchoNous raises $60M to launch handheld ultrasound tool". Puget Sound Business Journal. July 2, 2021.
- 1 2 Park, Andrea (August 18, 2021). "EchoNous scales up portable ultrasound platform with FDA OK for full-body probe". Fierce Biotech.
- ↑ "Medical device maker EchoNous raises $57M Series D". Puget Sound Business Journal. September 28, 2022.
- 1 2 Schubert, Charlotte (September 28, 2022). "Startup developing a hand-held ultrasound tool for the bedside lands $57M". GeekWire.
- ↑ Park, Andrea (August 19, 2022). "EchoNous brings AI ultrasound system to off-the-shelf Samsung devices". Fierce Biotech.
- 1 2 Schubert, Charlotte (July 13, 2023). "EchoNous, maker of an AI-powered portable ultrasound system, raises $7M". GeekWire.
- ↑ "510(k) Premarket Notification: K233826". U.S. Food and Drug Administration.
- ↑ "510(k) Premarket Notification: K242321". U.S. Food and Drug Administration.
- ↑ "Clinical validation of an artificial intelligence-assisted algorithm for automated estimation of left ventricular ejection fraction in real-world echocardiography". European Heart Journal - Digital Health.
- ↑ "A Novel Handheld Echocardiography Device with Continuous-Wave Doppler Capability: Implications for the Evaluation of Aortic Stenosis Severity". Journal of the American Society of Echocardiography. December 2022.